SNCAIP antibody (Internal Region)

Catalog No. ABIN350932

Product Details anti-SNCAIP Antibody

Target: SNCAIP (Synuclein, alpha Interacting Protein (SNCAIP))

Binding Specificity: Internal Region

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This SNCAIP antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC)

Specificity: Specific for Synphilin-1.

Cross-Reactivity: Human

Cross-Reactivity (Details): Other species not yet tested.

Purification: IgG

Immunogen: A synthetic peptide from the internal region of human Synphilin-1 (Synphilin 1, alpha synuclein interacting protein) conjugated to an immunogenic carrier protein was used as the antigen.

Isotype: IgG

Application Details

Application Notes: IHC, WB. A concentration of 10-50 μg,ml is recommended. The optimal concentration should be determined by the end user. Not yet tested in other applications.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Reconstitute in 500 μL of sterile water. Centrifuge to remove any insoluble material.

Handling Advice: Avoid freeze and thaw cycles.

Storage: 4 °C/-20 °C

Storage Comment: Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.

Expiry Date: 12 months

Target Details for SNCAIP

Target: SNCAIP (Synuclein, alpha Interacting Protein (SNCAIP))

Alternative Name: Synphilin-1 (SNCAIP Products)

Synonyms: sncaip antibody, MGC88953 antibody, SNCAIP antibody, LOC100221074 antibody, SYPH1 antibody, Sph1 antibody, Syph1 antibody, 2810407O15Rik antibody, 4933427B05Rik antibody, BB104594 antibody, synuclein alpha interacting protein antibody, synuclein, alpha interacting protein antibody, synuclein, alpha interacting protein (synphilin) antibody, SNCAIP antibody, sncaip antibody, Sncaip antibody

Background: Tissue specificity: Widely expressed, with highest levels in brain, heart and placenta. Defects in SNCAIP are a cause of Parkinson disease (PD). PD is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. Constructs encoding portions of SNCA and SNCAIP co-transfected in mammalian cells promote cytosolic inclusions resembling the Lewy bodies of Parkinson disease. Coexpression of SNCA, SNCAIP, and PARK2 result in the formation of Lewy body-like ubiquitin-positive cytosolic inclusions. Familial mutations in PARK2 disrupt the ubiquitination of SNCAIP and the formation of the ubiquitin-positive inclusions. These results provide a molecular basis for the ubiquitination of Lewy body-associated proteins and link PARK2 and SNCA in a common pathogenic mechanism through their interaction with SNCAIP.,Neurodegeneration,Alpha-synuclein-interacting protein, SNCAIP

UniProt: Q9Y6H5